ZEMANEK, David, Jaroslav JANUSKA, Tomáš HONEK, Karol CURILA, Milos KUBANEK, Stepanka SINDELAROVA, Lucie ZAHALKOVA, Petr KLOFAC, Eliska LASTUVKOVA, Eva LICHNEROVA, Renata AIGLOVA, Jan LHOTSKY, Jiri VONDRAK, Gabriela DOSTALOVA, Milos TABORSKY, David KASPER and Ales LINHART. Nationwide screening of Fabry disease in patients with hypertrophic cardiomyopathy in Czech Republic. ESC Heart Failure. San Francisco: Wiley Periodicals, 2022, vol. 9, No 6, p. 4160-4166. ISSN 2055-5822. Available from: https://dx.doi.org/10.1002/ehf2.14135.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Nationwide screening of Fabry disease in patients with hypertrophic cardiomyopathy in Czech Republic
Authors ZEMANEK, David (203 Czech Republic), Jaroslav JANUSKA (203 Czech Republic), Tomáš HONEK (203 Czech Republic, belonging to the institution), Karol CURILA (203 Czech Republic), Milos KUBANEK (203 Czech Republic), Stepanka SINDELAROVA (203 Czech Republic), Lucie ZAHALKOVA (203 Czech Republic), Petr KLOFAC (203 Czech Republic), Eliska LASTUVKOVA (203 Czech Republic), Eva LICHNEROVA (203 Czech Republic), Renata AIGLOVA (203 Czech Republic), Jan LHOTSKY (203 Czech Republic), Jiri VONDRAK (203 Czech Republic), Gabriela DOSTALOVA (203 Czech Republic), Milos TABORSKY (203 Czech Republic), David KASPER (203 Czech Republic) and Ales LINHART (203 Czech Republic, guarantor).
Edition ESC Heart Failure, San Francisco, Wiley Periodicals, 2022, 2055-5822.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30201 Cardiac and Cardiovascular systems
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 3.800
RIV identification code RIV/00216224:14110/22:00128280
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1002/ehf2.14135
UT WoS 000852286600001
Keywords in English Fabry disease; Hypertrophic cardiomyopathy; Screening; Alpha-galactosidase; Lyso-Gb(3); Genetic testing
Tags 14110115, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 25/1/2023 14:35.
Abstract
Aims Fabry disease (FD) is a rare X-linked genetic disorder caused by a-galactosidase A (AGALA) deficiency. Whereas 'classic' variant has multisystemic manifestation, the more recently described 'later-onset' variant is characterized by predominant cardiac involvement that often mimics hypertrophic cardiomyopathy (HCM). Methods and results Consecutive unrelated patients with HCM were screened for FD in 16 (out of 17) cardiac centres in the Czech Republic covering specialized cardiology care from June 2017 to December 2018. AGALA activity and globotriaosylsphingosine (lyso-Gb(3)) levels were measured in all subjects using the dry blood spot method. FD was suspected in male patients with AGALA activity <1.2 mu mol/h/L and in females with either low AGALA activity or lyso-Gb(3) > 3.5 ng/mL. Positive screening results were confirmed by genetic testing. We evaluated 589 patients (390 males, 66%) with HCM (mean maximal myocardial thickness 19.1 +/- 4.3 mm). The average age was 58.4 +/- 14.7 years. In total, 17 patients (11 males, 6 females) had a positive screening result, and subsequently, six of them (four males and two females) had a genetically confirmed pathogenic GLA mutation (total prevalence of 1.02%). Five of these patients were carrying the p.N215S mutation known to cause a typical later-onset cardiac FD. Conclusions We confirmed the prevalence of FD repeatedly reported in previous screening programmes (approximately 1% irrespective of gender) in a non-selected HCM population in Central Europe. Our findings advocate a routine screening for FD in all adult patients with HCM phenotype including both genders. The dry blood spot method used led to identification of clearly pathogenic variants.
PrintDisplayed: 21/7/2024 11:29